All In Biotech

Free tool

FAERS Monitor: Ovidrel

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 021149 or its brand name (Ovidrel, Choriogonadotropin Alfa). Reports on generic versions are filed under their own applications.

Reports

1,163

Serious

924

79% of reports

Hospitalization

583

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • ovarian hyperstimulation syndrome448
  • ascites83
  • abdominal distension74
  • abdominal pain70
  • nausea62
  • off label use62
  • dyspnoea51
  • pleural effusion48
  • abortion spontaneous46
  • maternal exposure during pregnancy40
  • headache38
  • vomiting37
  • maternal exposure before pregnancy32
  • abdominal pain lower31
  • dizziness30

Reports by year received

View as table
YearReports
20045
20054
20066
200716
20088
200911
201010
201118
201227
201330
201426
201511
201624
201715
201832
201964
202043
202184
2022163
2023150
2024175
2025114
2026127

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,996 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ovarian hyperstimulation syndromeSignal4484302.33949.81,553,286
maternal exposure before pregnancySignal3285.160.42,565
ascitesSignal8351.241.64,030
abdominal pain lowerSignal3122.215.7607
abortion spontaneousSignal4620.815.7847
pleural effusionSignal4814.310.8581
abdominal distensionSignal7412.810.3799
maternal exposure during pregnancySignal408.16.0244
abdominal painSignal705.44.3252
dyspnoea511.61.212
vomiting371.41.04
nausea621.41.17
off label use621.31.04
headache381.10.80
dizziness301.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.